Explore
Validate
Learn
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-84890 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ZNRF2 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Immunogen sequence: NSSSGPYGSQ DSVHSSPEDG GGGRDRPVGG SPGGPRLVIG SLPAHLSPHM FGGFKCPVCS KFVSSDEMDL HLVMCLTK
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 0.1 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
Li M, Zhang S, Ma Y, Yang Y, An R
Oncology reports 2021 May;45(5)
Oncology reports 2021 May;45(5)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of ZNRF2 in human testis using ZNRF2 Polyclonal Antibody (Product # PA5-84890) shows moderate cytoplasmic positivity in cells in seminiferous ducts.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4. ZNRF2 functions as a direct target of hsa-miR-105 in epithelial ovarian cancer (EOC) cells. (A) Prediction of putative target genes of hsa-miR-105 by three online programs. (B) Transcriptional expression levels of 17 candidate genes in four pair of paclitaxel (PTX)-responsive and PTX-resistant EOC tissues were analyzed using real-time RT-qPCR (*P
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5. Stable knockdown of ZNRF2 potentiates paclitaxel (PTX) responsiveness in hsa-miR-105-delepted epithelial ovarian cancer (EOC) cells. (A) Establishment of EOC cells that were stably deprived of ZNRF2 expression was verified using western blot analysis. (B) Forty-eight hours after transfection with the indicated oligonucleotides, EOC cells were seeded in 96-well plates at the density of 5x10 3 cells/well. Cells were then exposed to different doses of PTX as indicated or DMSO for 24 h, followed by measurement of cell viability using Cell Counting Kit-8 (*P
